aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
2020 · Journal of Hepatology · 331 citations
https://doi.org/10.1016/j.jhep.2020.07.025
L
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
304
Papers
6.4K
Citations
40
h-index
112
i10-index
Lai Wei is an academic researcher from National Center for Chronic and Noncommunicable Disease Control and Prevention. The author has contributed to research in topics: Hepatitis C virus research & Hepatitis B Virus Studies & Liver Disease Diagnosis and Treatment. The author has an h-index of 40, co-authored 259 publications.
ORCID: 0000-0003-2326-1257Papers by this author
worksGuideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
2017 · Journal of Clinical and Translational Hepatology · 275 citations
https://doi.org/10.14218/jcth.2016.00019
APASL consensus statements and recommendation on treatment of hepatitis C
2016 · Hepatology International · 221 citations
https://doi.org/10.1007/s12072-016-9717-6
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries
2019 · Clinical Gastroenterology and Hepatology · 106 citations
https://doi.org/10.1016/j.cgh.2019.07.010
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
2016 · Hepatology International · 93 citations
https://doi.org/10.1007/s12072-016-9736-3
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia
2025 · Hepatology International · 42 citations
https://doi.org/10.1007/s12072-024-10773-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat